Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients

Transplant International

Volumn 24, Issue 6, 2011, Pages 536-547

  Brouard, Sophie ^a   Le Bars, Alice ^b   Dufay, Alexandre ^a,c,d   Gosselin, Morgane ^a,c,d   Foucher, Yohann ^a,c,e   Guillet, Marina ^b   Cesbron Gautier, Anne ^f   Thervet, Eric ^g,h   Legendre, Christophe ^g,h   Dugast, Emilie ^a   Pallier, Annaick ^a   Guillot Gueguen, Cécile ^c   Lagoutte, Laetitia ^b   Evanno, Gwenaelle ^b   Giral, Magali ^a,c,d,i   Soulillou, Jean Paul ^a,c,d  

^a INSERM   (France)

^b TcLand Expression   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e Universite de Nantes   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

human; immunology; kidney; tolerance; transplantation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; SCHOOL CHILD; TRANSPLANTATION TOLERANCE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CALCINEURIN; CHILD; FEMALE; GENE EXPRESSION PROFILING; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS;

EID: 79955563324     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01251.x     Document Type: Article

References (33)

1. Vincenti F, Kirk AD,. What's next in the pipeline. Am J Transplant 2008; 8: 1972.
2. Opelz G,. Influence of treatment with cyclosporine, azathioprine and steroids on chronic allograft failure. The Collaborative Transplant Study. Kidney Int Suppl 1995; 52: S89.
3. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623.
4. Soulillou J, Giral M,. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001; 72 (12 Suppl): S89.
5. Morelon E, Stern M, Kreis H,. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343: 225.
6. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72: 787.
7. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP,. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403.
8. Halloran P,. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
9. Halloran PF, Bromberg J, Kaplan B, Vincenti F,. Tolerance versus immunosuppression: a perspective. Am J Transplant 2008; 8: 1365.
10. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
11. Hariharan S, Stablein DE,. Improvements in long-term renal transplant graft survival. Am J Transplant 2005; 5: 630.
12. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP,. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
13. Grinyo JM, Gil-Vernet S, Cruzado JM, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 2003; 16: 820.
14. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309.
15. Roussey-Kesler G, Giral M, Moreau A, et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006; 6: 736.
16. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448.
17. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
18. Tibshirani R, Hastie T, Narasimhan B, Chu G,. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 6567.
19. Development Core Team (2008). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing V, Austria. ISBN 3-900051-07-0, URL:.
20. Pan W, Chappell R,. A nonparametric estimator of survival functions for arbitrarily truncated and censored data. Lifetime Data Anal 1998; 4: 187.
21. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89.
22. Kingsley CI, Nadig SN, Wood KJ,. Transplantation tolerance: lessons from experimental rodent models. Transpl Int 2007; 20: 828.
23. Ashton-Chess J, Brouard S, Soulillou JP,. Is clinical tolerance realistic in the next decade? Transpl Int 2006; 19: 539.
24. Moreso F, Serõn D G-VS, Riera L, et al. Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients. Nephrol Dial Transplant 1999; 14: 930.
25. Stallone G, Infante B, Gesualdo L,. Older donors and older recipients in kidney transplantation. J Nephrol 2010; 23 (Suppl. 15): S98.
26. Remuzzi G, Cravedi P, Perna A, et al. Long-term outcome of renal transplantation from older donors. N Engl J Med 2006; 354: 343.
27. Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845.
28. Ballet C, Roussey-Kesler G, Aubin JT, Brouard S, et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant 2006; 6: 2796.
29. Pallier A, Hillion S, Danger R, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503.
30. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848.
31. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836.
32. Steger U, Denecke C, Sawitzki B, Karim M, Jones ND, Wood KJ,. Exhaustive differentiation of alloreactive CD8+ T-cells: critical for determination of graft acceptance or rejection. Transplantation 2008; 85: 1339.
33. Ashton-Chess J, Giral M, Mengel M, et al. Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. J Am Soc Nephrol 2008; 19: 1116.